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Abstract
Purpose Our objective was to highlight the importance of
database selection in observational research and to deter-
mine the incidence of corticosteroid-related events in
patients exposed to fluticasone propionate intranasal spray
(FPNS) compared with other intranasal steroids (INS).
Methods After a feasibility study using an electronicmedical
record database in the UK (1990–2002), a retrospective cohort
study was conducted using a large administrative claims data-
base in the USA from 1994 to 2002 comparing the incidence
and rate ratios of steroid-related events among intermittent,
sub-chronic, and chronic FPNSuse and other INSuse episodes.
Results Most patients used INS intermittently; power was
low to evaluate risk associated with chronic use. Signifi-
cantly elevated adjusted rate ratios were observed in the US
study comparing FPNS with other INS for hypercorticism,
sinusitis, abscess, and empyema, as well as a significantly
decreased rate ratio for cataracts. The US claims database
provided greater granularity on covariates and markers of
severity to improve control of confounding for this study
and time period, but neither database was able to assess the
indication for prescription and the UK study could not
address the use of INS without a prescription.
Conclusions The FPNS results were consistent with the
risk profile for INS and did not raise any new safety signals
at the time of study conduct, which is consistent with the
current safety profile. We were not able to discern the
extent of potential off-label use of FPNS or other INS.
Differences in the available data and healthcare systems
highlight important considerations for database selection in
the feasibility phase to assess the precision and limitations
prior to formal risk evaluation.
Key Points
The results of these studies, along with findings from
other observational studies and randomized longer
duration clinical studies, were consistent with the
labeled risk profile for intranasal steroids and did not
raise any new safety signals associated with the use
of fluticasone propionate intranasal spray.
Database selection can benefit from a feasibility
phase to assess the precision based on number of
events of interest in the target population, prescribing
patterns (e.g., extent of channeling), and availability
of potential confounders of interest and
detail/completeness of data prior to embarking upon
a full comparative safety risk evaluation.
1 Introduction
To illustrate the importance of database selection and
highlight the differences between databases, we present
lessons gleaned from conducting similar analyses with
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nearly identical designs in different databases, evaluating
the use and effects of intranasal corticosteroids (INS). In
mid-2000, we conducted two parallel retrospective cohort
studies of the safety of fluticasone propionate intranasal
spray (FPNS) compared with other INS. We utilized the
UK Clinical Practice Research Datalink (CPRD; formerly
known as General Practice Research Database [GPRD])
and a large US managed care database to evaluate the
utilization and safety of FPNS.
INS are common treatments for rhinitis (allergic and
non-allergic), providing broad relief of symptoms, includ-
ing nasal congestion, sneezing, nasal itching, and rhinor-
rhea [1]. INS are a mainstay of pharmacotherapy in adults
and children; they have well-established efficacy and tol-
erability, yet concerns remain among patients and health-
care providers regarding systemic effects, particularly with
concurrent exposure to oral and high-dose inhaled corti-
costeroids [2, 3]. Systemic concerns, particularly with
chronic use, include growth inhibition via suppression of
the hypothalamus–pituitary–adrenal axis, decreased bone
mineral density (i.e., fractures and osteoporosis), ocular
effects (i.e., cataracts, glaucoma, and myopathy), hyper-
tension, hyperglycemia, and bruising [2, 4].
FPNS is an INS that was approved in the 1990s for use
among adults and children aged 4 years and older. In the
USA, FPNS is a prescription medication approved for the
treatment of seasonal and chronic allergic and non-allergic
rhinitis. In the UK, FPNS is a non-prescription medication
approved for prophylaxis and treatment of seasonal allergic
rhinitis and perennial rhinitis. FP nasal drops are addi-
tionally approved for the regular treatment of nasal polyps
in the UK. FP is one of the more potent glucocorticos-
teroids available for prescription [5]. Clinical trials of
FPNS compared with placebo [6–10], including year-long
trials [11, 12], did not show evidence of growth changes,
bone density effects, or ocular effects in children or adults.
The primary objectives of the studies, when conducted,
were to characterize and compare users of FPNS and users
of other non-FP INS in terms of demographics and patterns
of use; to determine the rates of events of interest among
FPNS compared with INS users with intermittent, sub-
chronic, and chronic steroid use; and to assess potential
effect modifiers of the association between INS use and
events of interest. The study in the UK CPRD database was
conducted only through the feasibility stage because of
limitations experienced in obtaining the occurrence of and
details from specialist physician encounters (e.g., proce-
dures) within the database; however, this work informed
the US study. Therefore, we briefly describe the general
design in the methods and main results of the UK analysis
to illustrate the primary objective of this paper: highlight-
ing the differences between the two databases and lessons
learned from conducting similar analyses with nearly
identical designs in different databases. A more detailed
description of the methodological nuances and results from
the UK feasibility study are provided in Resource 2 of the
Electronic Supplementary Material (ESM).
2 Methods
2.1 Data Sources
The GPRD, now CPRD, contains computerized healthcare
information entered by general practitioners (GPs) in the
UK [13, 14], including demographics, prescriptions, clini-
cal events, preventive care, specialist referrals, and hospital
admissions (though not all procedures, laboratory tests, or
diagnoses recorded during a hospitalization). All members
of the population are registered with a single practice,
which centralizes the medical information from GPs, spe-
cialist referrals, and hospital attendance. An approximate
6 % sample of the UK population, with patient records in
CPRD from 1 January 1990 to 31 January 2002 was used to
develop the overall UK study cohort. The protocol for the
UK study was submitted to the CPRD Scientific and Eth-
ical Group for review and comments.
A large US managed care database (‘i3 Magnifi’), with
claims for approximately 6 million lives (2 million in any
given year) in 22 states during the study timeframe, was
used for the primary US study. The database contained
linked administrative claims data from ambulatory and
inpatient sources, including diagnoses, procedures, phar-
macy, and hospitalizations. Patient records from 1 January
1994 to 30 September 2002 were used to develop the
overall US study cohort. Approximately 17 % of the
database membership belonged to a Medicare Risk plan,
including claims for adults aged C65 years. Roughly 4 %
of the population belonged to a Medicare Supplement Plan
and were excluded due to the possibility of incomplete
records.
2.2 Study Design and Population
Parallel study designs were used for the UK feasibility and
US studies, which generally only differed on the detail of
data provided by the individual databases, e.g., GP-recor-
ded information versus healthcare insurance claims,
including information from specialist physicians. The UK
study was conducted through the feasibility stage and
informed the US study regarding the ability to control
confounding factors. Analyses included two inception
cohorts: patients initiated on FPNS and patients initiated on
another INS (not FPNS) with no use of any INS in the year
prior to study initiation. Patients initiating FPNS or another
INS during the analysis period (UK: 1 January 1990 to 1
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January 2002; USA: 1 January 1995 through 30 September
2002) were identified, and the first FPNS or other INS
prescription claim was assigned as the index date and
determined cohort placement.
Patients without continuous coverage in the database
(USA: 12 months prior) before the index date were
excluded, as were patients aged \4 years at index (see
Online Resource 2 in the ESM for specifics of the UK
study).
2.3 Exposure
Patient histories were divided into FPNS or other INS use
episodes (intermittent, sub-chronic, or chronic use) of
consecutive prescriptions, with no more than 60 days
between prescriptions (between fill dates or repeat pre-
scriptions) to be considered in the same episode. A break of
more than 60 days constituted a separate episode. Inter-
mittent exposure was defined as exposure to the same drug
(FPNS or other INS) consisting of one to three consecutive
prescriptions, sub-chronic four to eight consecutive pre-
scriptions, and chronic nine or more consecutive pre-
scriptions. A span of at least 6 months had to elapse
between the first and last prescription claim of a chronic
episode. The first exposure episode (i.e., episode including
the index date) was required to have at least 120 days free
from exposure to another INS after the last claim in the
episode. If a patient in the FPNS cohort received another
INS during the study period, he or she was censored at the
date of other INS dispensing.
2.4 Outcomes
The same outcomes were assessed in both studies: catar-
acts, glaucoma, nasal septum perforation, hypercorticism
(Cushing’s syndrome), adrenal insufficiency, fractures (hip,
wrist, or vertebral) as proxies for osteoporosis, sinusitis
(acute and chronic), and infectious complications of
sinusitis (cellulitis [periorbital], empyema [maxillary],
abscess [brain], meningitis, encephalitis). Otitis media,
asthma, and diabetes were also assessed in the UK feasi-
bility study. Outcomes were identified by International
Classification of Diseases, ninth edition (ICD-9) codes in
the US database, along with drug codes as a proxy measure
for glaucoma diagnosis.
2.5 Analysis
Patients in the FPNS and other INS cohorts were compared
on sex, age, comorbid diseases (diagnosed prior to episode
index date), oral corticosteroid (OCS) and inhaled corti-
costeroid (ICS) use, use of other medications, and prior
healthcare utilization, as well as region, seasonality
(month) of first INS prescription, number of INS pre-
scriptions per year, and average number of days between
prescription refills (stratified by eligible time). Risk factors
for each outcome were identified utilizing an historical
cohort (Online Resource 1 in the ESM). Patients with key
variables missing (e.g., demographics) were not eligible for
the analysis. Poisson regression modeling estimated the
relative rate adjusting for the potential confounders with
95 % confidence intervals (CIs) specific to each outcome
(for details see Online Resource 1 in the ESM). Manual
stepwise regression identified risk factors/modifiers that
were independently associated with the endpoint under
evaluation (threshold of p\ 0.1 for inclusion in modeling).
Covariates known to be major contributing factors were
forced into the model. An alpha level of 0.05 was used to
test for statistical significance.
Outcomes were analyzed based on exposure episodes,
with one episode per person randomly selected from all
eligible episodes. One episode per person was randomly
selected to provide a more representative sample of the
INS user population and avoid correlated multiple epi-
sodes, as the vast majority of INS utilization is inter-
mittent based on exposure to triggers. Capture of
incident events began with the first prescription in the
episode and terminated 120 days (30 days of medication
use plus a 90-day observance tail) after the last pre-
scription. Episodes with fewer than 120 days of eligi-
bility after the last prescription were excluded from the
outcome analyses, as were episodes with exposures to
another study medication during the 120-day assessment
period. Person-time accumulated from the episode index
date to the first of an outcome event date or a set time
(USA: 120 days) after the last prescription when the
observations were censored.
Incidence rates and rate ratios (RRs) were calculated for
events during the randomly selected episodes overall as
well as stratified by episodes that were intermittent, sub-
chronic, and chronic use episodes. Each outcome was
analyzed separately. Patients with the outcome of interest
prior to the cohort index date (USA: 12 months prior) or
prior to an episode start date (USA: 12 months prior) were
excluded from the analysis of that specific outcome to rule
out prevalent conditions.
3 Results
The UK feasibility study included 333,182 (FPNS: 62,380;
other INS 270,802) intranasal corticosteroid users. The US
study contained 126,613 INS users (FPNS 52,870; other
INS 73,743), who were predominantly female, distributed
throughout the study age range (C4 years), and evenly
distributed by season of INS initiation (Table 1).
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3.1 UK Feasibility Analysis
Comparing FPNS with other INS users, elevated incidence
rates for the following events were observed: abscess, dia-
betes, nasal septum perforation, osteoporosis, and chronic
sinusitis. Cox models for randomly selected intermittent
episodes compared the time to the outcome of interest
adjusting for prevalence of all other events of interest, age,
sex, OCS use, ICS use, prescription antihistamine use, nasal
polyps, and number of visits to a GP in the prior 12 months.
Crude hazard ratios (HRs) comparing FPNS with other INS
suggested that use of FPNSwas associated with an increased
risk of nasal septum perforation (FPNS n = 198, INS n = 643
INS; HR 1.39, 95 % CI 1.18–1.63), osteoporosis (FPNS n =
60, INS n = 161; HR 1.66, 95 % CI 1.23–2.23), chronic
sinusitis (FPNS n = 280, INS n = 704; HR 1.80, 95 % CI
1.57–2.07), diabetes (FPNS n = 76, INS n = 281; HR 1.19,
95 % CI 0.92–1.53), and abscess (FPNS n = 9, INS n = 26;
HR 1.55, 95 % CI 0.73–3.31). The final adjusted HRs for
these outcomes were all less than 1.50, suggesting weak
associations with FPNS exposure. Additional results and
discussion of the UK feasibility study are posted on the
GlaxoSmithKline Clinical Study Register (http://download.
gsk-clinicalstudyregister.com/files/ed97c9c9-9928-4ee0-
8f5f-72bbb212a638) and described in Online Resource 2
(ESM).
The reduction from crude to adjusted HRs suggested
that some confounding was removed; however, concern
remained about residual confounding by indication/severity
given the limited detailed information from CPRD avail-
able at the time (discussed below) for modeling. Based on
the prevalent conditions in year prior to the index date,
including evidence of prevalent asthma, acute and chronic
sinusitis, nasal septum perforation, and chronic and acute
otitis, allergic rhinitis appeared to be more severe among
patients prescribed FPNS than another INS.
3.2 US Analysis
While age, sex, acute sinusitis, OCS, ICS, antihistamine
prescriptions, nasal polyps, prevalent conditions, and GP
visits were included in the UK models, the US database
allowed a more granular characterization of patients’ risk
profiles, including dispensed medications and additional
comorbid diagnoses (Online Resource 1 [ESM]), along
with utilization and procedure data from both primary and
specialist care, which consequently allowed for better
control and clearer understanding of potential confounding
factors. The covariates used in each model were outcome
specific (Online Resource 1 [ESM]), such that they were
associated with both the outcome and the probability of
receiving a FPNS prescription.
After adjusting for risk factors identified in the historical
cohort, five outcomes (hypercorticism, nasal septum per-
foration, sinusitis, abscess, and empyema) were statistically
significantly more likely to occur in FPNS than INS
patients, though absolute risks were lower than in the UK
feasibility study (Table 2). The relative risk of nasal sep-
tum perforation was 1.10, 95 % CI 1.00–1.22, as compared
with the UK study (HR 1.41, 95 % CI 1.21–1.67). Similar
reductions in the adjusted risk were also observed for
sinusitis, osteoporosis, and abscess when comparing the US
and UK studies (Fig. 1). Adrenal insufficiency and
encephalitis occurred more frequently among FPNS
patients, though 95 % CIs included the null value. In
contrast, FPNS patients were significantly less likely to
have received a diagnosis for cataracts than patients taking
other INS.
Nearly 86 % of FPNS patients and 84 % of INS patients
received only one prescription during the selected episode
for the overall analysis. Of the 126,613 total patients in the
study, roughly 97 % of FPNS and INS patients were cat-
egorized as intermittent users, 2.5 % as sub-chronic users,
and 0.5 % as chronic users. After stratification by usage,
intermittent users were found to have roughly the same
Table 1 US study population (US analysis)
FPNS cohort INS cohort Total
52,870 73,743 126,613
Male 21,877 (41.4) 30,245 (41.0) 52,122 (41.2)
Age (years)
4–14 5755 (10.9) 8751 (11.9) 14,506 (11.5)
15–24 4269 (8.1) 5332 (7.2) 9601 (7.6)
25–34 6842 (12.9) 8118 (11.0) 14,960 (11.8)
35–44 10,827 (20.5) 14,066 (19.1) 24,893 (19.7)
45–54 10,684 (20.2) 13,916 (18.9) 24,600 (19.4)
55–64 6252 (11.8) 8223 (11.2) 14,475 (11.4)
65–74 4971 (9.4) 8672 (11.8) 13,643 (10.8)
75–84 2616 (4.9) 5264 (7.1) 7880 (6.2)
C85 654 (1.2) 1401 (1.9) 2055 (1.6)
Region
Northeast 105 (0.2) 203 (0.3) 308 (0.2)
Midwest 15,903 (30.1) 21,525 (29.2) 37,428 (29.6)
South 35,671 (67.5) 49,529 (67.2) 85,200 (67.3)
West 1191 (2.3) 2486 (3.4) 3677 (2.9)
Seasona
Winter 14,280 (27.0) 20,934 (28.4) 35,214 (27.8)
Spring 15,455 (29.2) 20,656 (28.0) 36,111 (28.5)
Summer 11,447 (21.7) 15,408 (20.9) 26,855 (21.2)
Fall 11,688 (22.1) 16,745 (22.7) 28,433 (22.5)
Data are presented as n (%)
FPNS fluticasone propionate intranasal spray, INS intranasal
corticosteroids
a Date of first FPNS/INS prescription
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adjusted and unadjusted RRs as in the overall analysis.
Outcomes that were statistically significant in the overall
analyses were significant in the intermittent user subgroup
(data not shown). A robust assessment of study outcomes
within these usage categories was not possible because of
the limited number of patients and outcomes in the sub-
chronic and chronic subgroups.
Roughly 85 % of FPNS and INS patients were dispensed
only an INS with no concurrent ICS or OCS dispensing
during a FPNS or INS episode. Approximately 8 % of FPNS
and INS patients were dispensed concurrent OCS, 4 %
received concurrent ICS, and 2 % received concurrent ICS
and OCS during the randomly selected analysis episode. For
patientswithout concurrent steroid exposure (i.e., only FPNS
or INS exposure), the adjusted RRs were similar to the
overall analysis, with the exception of hypercorticism and
empyema, which were decreased and not statistically sig-
nificant (RR 2.12, 95 %CI 0.75–5.97 for hypercorticism and
RR 1.60, 95 % CI 0.87–2.94). We were unable to calculate
adjusted RRs by concurrent corticosteroid stratum (ICS,
OCS, and ICS andOCS) because the numbers of events were
insufficient to provide meaningful results, including many
strata with zero events. Crude RRs by concurrent corticos-
teroid stratum were not statistically different between FPNS
and INS users, and they were generally based on small
numbers of events (data not shown).
We explored the effect of both episode type and con-
current corticosteroid (ICS and/or OCS) use, and patients
were divided into categories by episode type and steroid
use. Only the category of intermittent non-concurrent
corticosteroid users could be reliably assessed as the other
sub-categories had only small numbers. Virtually the same
RRs were found, and the same trend of significantly dif-
ferent outcomes was observed for intermittent non-con-
current steroid users as all non-concurrent steroid users
(data not shown). Data not presented here on episode type,
concurrent corticosteroid use, and the combined effect, are
described in the ESM.
4 Discussion
Despite the established safety of INS, concerns remain
regarding systemic effects reported with concurrent corti-
costeroids use [2]. We present two parallel retrospective
cohort studies of the safety of FPNS versus other INS in the
UK and USA, emphasizing the importance of database
selection and adding to the existing literature on INS
safety. The conclusion drawn from these complementary
sources was a reassuring safety profile for FPNS and that
the vast majority of patients used the medicine in inter-
mittent episodes. Although these data are from the 1990s
and early 2000s, and patterns of use and healthcare may
have evolved somewhat, the conclusion drawn from these
analyses is consistent with the current safety profile of INS.
The databases utilized in the UK feasibility and US
primary analysis recorded different details regarding
exposures, outcomes, and confounders during the study
period, as well as different healthcare delivery systems
with varying incentives for prescribing choices that influ-
enced the interpretability of study results. For example, the
UK database contained data input by GPs, including
medications prescribed and referrals to specialists, while
the US database contained pharmacy and specialist
Table 2 Event rates from randomly selected intranasal corticosteroids exposure episodes (US analysis)
Events FPNS cohort (n = 52,870) INS cohort (n = 73,743) Crude rate ratio
# of Events PY Rate/10,000 PY # of Events PY Rate/10,000 PY FPNS vs INS
RR (95 % CI)
Adrenal insufficiency 14 18,701 7 13 26,224 5 1.51 (0.71–3.21)
Cataract 483 18,088 267 992 24,785 400 0.67 (0.60–0.74)
Fracture 134 18,714 72 180 26,184 69 1.04 (0.83–1.30)
Glaucoma 241 18,294 132 378 25,400 149 0.89 (0.75–1.04)
Hypercorticism 19 18,845 10 10 26,387 4 2.66 (1.24–5.72)
Nasal septum perforation 745 17,998 414 939 25,382 370 1.12 (1.02–1.23)
Osteoporosis 59 18,775 31 79 26,315 30 1.05 (0.75–1.47)
Sinusitis 5870 12,719 4615 7710 18,556 4155 1.11 (1.07–1.15)
Abscess 2076 15,503 1339 2562 21,977 1166 1.15 (1.08–1.21)
Cellulitis 36 18,837 19 60 26,371 23 0.84 (0.56–1.27)
Empyema 30 18,859 16 22 26,401 8 1.91 (1.10–3.31)
Encephalitis 5 18,879 3 3 26,426 1 2.33 (0.56–9.76)
Meningitis 8 18,869 4 18 26,412 7 0.62 (0.27–1.43)
FPNS fluticasone propionate intranasal spray, INS intranasal corticosteroids (non-FP), RR rate ratio, PY patient years
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physician claims, including diagnoses, procedures, medi-
cations dispensed, and specialist healthcare utilization.
Neither database provided the indication for the specific
FPNS or INS prescription, and we could not examine use
without a prescription in the UK. After adjustment in the
UK study, concern remained about residual confounding
given the limited detail about the indication and clinical
severity in the electronic medical records. It is possible that
restriction of newer or more expensive therapies, such as
FPNS, in the UK health system to patients who remain
symptomatic while receiving cheaper medicines incen-
tivized GP prescribing of FPNS to more severe patients and
caused channeling or confounding by severity. Higher
baseline prevalence of conditions was observed comparing
FPNS with other INS in the UK study: acute sinusitis (31.6
vs. 28.9 %), asthma (21.6 vs. 16.0 %), chronic sinusitis
(2.7 vs. 1.1 %), nasal septum perforation (1.5 vs. 0.7 %),
and chronic (2.0 vs. 1.3 %), and acute otitis (15.4 vs.
11.0 %). The US managed care database provided addi-
tional information on confounding variables during the
study period, with detailed information from specialist
claims, including procedure codes (e.g., nasal polyp or
sinus surgery), providing unique detail not captured in the
CPRD.
The adjusted HR for chronic sinusitis in the UK study was
1.40 (95 %CI 1.23–1.63) and suggestedFPNSwasprescribed
more often than other INS after multiple acute events (con-
founding by severity). In the US study, the adjusted RR for
sinusitis, 1.10 (95 % CI 1.07–1.14), was lower than that
observed in the UK analysis, with the list of covariates eval-
uated for inclusion in the US multivariate model extended to
include age, sex, past and concurrent steroid use, interacting
Fig. 1 Adjusted rate ratios and 95 % confidence intervals associated
with fluticasone propionate intranasal spray exposure for selected
outcomes compared with other intranasal corticosteroid exposure (US
analysis). US study results adjusted for outcome specific covariates
(supplemental Table 1)
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drugs, asthma, cystic fibrosis, Kartagener’s, immune system
disorders, chemotherapy, upper respiratory infections,
immunosuppressants, HIV/AIDS, region, and season. Age,
sex, region, season, asthma, upper respiratory infections,
recent past ICS use, concurrent corticosteroid use (all cate-
gories), itraconazole, and ketoconazole were all found to be
independent risk factors in the multivariate model. Similar
attenuation with the more extensive US list of covariates was
observed for nasal septum perforation and abscess.
Approximately 97 % of subjects in the US study were
categorized as intermittent users and presented challenges
for study outcomes, for example, fracture, which depend
upon a longer exposure window to examine a biologically
plausible mechanism associated with chronic use of INS. A
minority of patients were also observed with concomitant
exposure to ICS and/or OCS (*14 %), which limited the
conclusions that could be drawn regarding total steroid
exposure from the concurrent steroid analysis. Further, in
these observational analyses, new users of FPNS may have
been exposed to another INS earlier due to the prescribing
patterns in clinical practice. In such situations, pragmatic
randomized study designs would be the optimal way to
overcome limitations of retrospective database design and
obtain a less biased assessment of comparative safety.
Despite the limitations, these studies analyzed large
patient populations and allowed a ‘real world’ comparison
of the effects of FPNS to other INS. Although the data
utilized in these analyses are older, the potential safety
issues with INS and ability to identify the safety outcomes
in both the UK and US database have not changed, and
these data confirmed the safety profile of INS.
In the overall assessment of the US study, rates of diag-
nosed hypercorticism, sinusitis, abscess, and empyema were
statistically elevated among the group dispensed FPNS
compared with the group dispensed INS. However, associ-
ations with hypercorticism and empyema were not statisti-
cally significant after the concomitant ICS- or OCS-exposed
patients were excluded, suggesting confounding due to
additional corticosteroid burden, though this is potentially
related to statistical power. Although sinusitis and the
associated nasal discharge is not a labeled indication, INS
may have been prescribed to manage the condition. There-
fore, we could not rule out the potential for off-label use,
challenging the temporal association between exposure and
outcome in a retrospective claim-based observational study.
5 Conclusion
The results of both studies were consistent with both the
labeled risk profile for INS during the observational study
timeframes and the current risk profile [2, 14–16], and did
not raise any new safety signals associated with FPNS use.
The parallel designs in two unique databases and somewhat
differing results highlight that variability in prescribing
practices, healthcare systems, and availability/extent of
detail in linked data are all important considerations for
choice of observational databases in the feasibility phase of
study design. A feasibility phase allows assessment of
precision and limitations based on number of events of
interest and extent of exposure (e.g., intermittent vs.
chronic use), profile of prescribing patterns based on dis-
ease severity (e.g., extent of channeling) over time, and
availability/details of potential confounders of interest
before the more appropriate database(s) is selected for a
full risk-evaluation study. These observational study data
presented for FPNS versus INS, considered in the context
of the healthcare systems, add to the evidence base of
randomized and observational studies informing decision
making for regulatory authorities, physicians, and patients.
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